News on Halozyme Therapeutics from BioPortfolio.com http://www.BioPortfolio.com Consolidated Halozyme Therapeutics news from BioPortfolio.com Wed, 10 Feb 2010 12:49:00 GMT en San Diegos Halozyme Therapeutics Seeks Biotech Cure for Cellulitehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034817&HITNO=0&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034817&THISHREF=http://c.moreover.com/click/here.pl%3fz2535991280%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034817&HITNO=0&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034817&THISHREF=http://c.moreover.com/click/here.pl%3fz2535991280%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comXconomy: Datamonitor: Roche - novel Herceptin formulation promises greater convenience on reports-research.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014493&HITNO=1&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014493&THISHREF=http://c.moreover.com/click/here.pl%3fz2524023494%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014493&HITNO=1&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014493&THISHREF=http://c.moreover.com/click/here.pl%3fz2524023494%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Roche to Plug Over $181M Into Manufacturing Sites to Produce Self-Administration Device fohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3989623&HITNO=2&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3989623&THISHREF=http://c.moreover.com/click/here.pl%3fz2512728511%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3989623&HITNO=2&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3989623&THISHREF=http://c.moreover.com/click/here.pl%3fz2512728511%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: San Diegos Halozyme Injects New Life into Old Drugshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3962312&HITNO=3&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3962312&THISHREF=http://c.moreover.com/click/here.pl%3fz2497171807%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3962312&HITNO=3&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3962312&THISHREF=http://c.moreover.com/click/here.pl%3fz2497171807%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comXconomy: Roche: novel Herceptin formulation promises greater conveniencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3961078&HITNO=4&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3961078&THISHREF=http://c.moreover.com/click/here.pl%3fz2496566752%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3961078&HITNO=4&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3961078&THISHREF=http://c.moreover.com/click/here.pl%3fz2496566752%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Halozyme Announces Research Alliance with BioAtla for Conditionally Active Biologicshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3954987&HITNO=5&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3954987&THISHREF=http://c.moreover.com/click/here.pl%3fz2493483672%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3954987&HITNO=5&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3954987&THISHREF=http://c.moreover.com/click/here.pl%3fz2493483672%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Halozyme Therapeutics and BioAtla sign research collaboration agreementhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3955537&HITNO=6&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3955537&THISHREF=http://c.moreover.com/click/here.pl%3fz2494082413%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3955537&HITNO=6&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3955537&THISHREF=http://c.moreover.com/click/here.pl%3fz2494082413%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Roche invests in production of new Herceptin formulationhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3959658&HITNO=7&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3959658&THISHREF=http://c.moreover.com/click/here.pl%3fz2495829102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3959658&HITNO=7&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3959658&THISHREF=http://c.moreover.com/click/here.pl%3fz2495829102%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmafocus: Roche (RHHBY): Novel Herceptin Formulation Promises Greater Conveniencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3956337&HITNO=8&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3956337&THISHREF=http://c.moreover.com/click/here.pl%3fz2494503573%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3956337&HITNO=8&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3956337&THISHREF=http://c.moreover.com/click/here.pl%3fz2494503573%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioSpace: Roche: novel Herceptin formulation promises greater conveniencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3951157&HITNO=9&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3951157&THISHREF=http://c.moreover.com/click/here.pl%3fz2490040179%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3951157&HITNO=9&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3951157&THISHREF=http://c.moreover.com/click/here.pl%3fz2490040179%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Roche: novel Herceptin formulation promises greater conveniencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3949186&HITNO=10&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3949186&THISHREF=http://c.moreover.com/click/here.pl%3fz2488972680%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3949186&HITNO=10&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3949186&THISHREF=http://c.moreover.com/click/here.pl%3fz2488972680%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Roche: novel Herceptin formulation promises greater conveniencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3949094&HITNO=11&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3949094&THISHREF=http://c.moreover.com/click/here.pl%3fz2488926103%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3949094&HITNO=11&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3949094&THISHREF=http://c.moreover.com/click/here.pl%3fz2488926103%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Roche invests about 190 Mio Swiss Francs in infusion-free administration device with new Herceptin formulationhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3950181&HITNO=12&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3950181&THISHREF=http://c.moreover.com/click/here.pl%3fz2489509419%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3950181&HITNO=12&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3950181&THISHREF=http://c.moreover.com/click/here.pl%3fz2489509419%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: Halozyme Therapeutics signs collaboration agreement with BioAtlahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3941099&HITNO=13&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3941099&THISHREF=http://c.moreover.com/click/here.pl%3fz2485329484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3941099&HITNO=13&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3941099&THISHREF=http://c.moreover.com/click/here.pl%3fz2485329484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Roche Prepares to Make Devices for Drug Using Halozyme Therapeutics Technologyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3939570&HITNO=14&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3939570&THISHREF=http://c.moreover.com/click/here.pl%3fz2484676922%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3939570&HITNO=14&MSIZE=60&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Halozyme%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3939570&THISHREF=http://c.moreover.com/click/here.pl%3fz2484676922%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comXconomy: